U.S. stocks rose; Vicor jumped 13.5% on a new license, while Generac surged 19.6% on an Amazon deal.

Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference T

Vera Therapeutics Inc. (NASDAQ:VERA) shares are trading lower on Tuesday, after initially spiking hi

Vera Therapeutics Phase 3 trial data show that Trutakna significantly reduces kidney disease progres

Vera Therapeutics takes a step toward securing full Food and Drug Administration approval for its in

Vera Therapeutics (VERA) shares ripped higher in premarket trading on September 15 as investors reac

Vera Therapeutics (NASDAQ:VERA) stock is down 2% to trade at $33.34, reversing earlier gains after d

Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 39.3% to $1.56 during Tuesday

TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints,

Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR, Prevented IgAN Disease Progr

JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and rai

BRISBANE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today an

BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a comme

The text discusses recent gains in the stock market, particularly for companies like Napco Security

Vera Therapeutics is upgraded to Buy following TRUTAKNA's FDA approval and encouraging eGFR data. Th

Wedbush analyst Laura Chico reiterates Vera Therapeutics (NASDAQ:VERA) with a Neutral and maintai

U.S. stocks up, Dow Jones 0.1% higher. HeartFlow (HTFL) shares rise 26.5% on better-than-expected ea

HC Wainwright & Co. analyst Arthur He maintains Vera Therapeutics (NASDAQ:VERA) with a Buy an

E. Ohman J or Asset Management AB grew its holdings in Vera Therapeutics, Inc. (NASDAQ: VERA) by 99.

Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:VERA) with a Neutral and lowers t

Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.52) per share which beat the analys

BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today ann

Vera Therapeutics NASDAQ: VERA said the U.S. Food and Drug Administration granted accelerated approv

BRISBANE, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today ann

BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commer

TD Cowen analyst Ritu Baral maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and raises the p

Guggenheim analyst Vamil Divan maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and raises th

Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:VERA) with a Neutral and raises the

US stock futures lower with Dow down 500 points. Kura Sushi shares drop after reporting worse-than-e

HC Wainwright & Co. analyst Arthur He maintains Vera Therapeutics (NASDAQ:VERA) with a Buy an

Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Tr

B of A Securities analyst Dina Ramadane maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and

Vera Therapeutics (VERA) stock jumps 9% following FDA accelerated approval for its kidney disease dr

The ​U.S. Food and Drug Administration ‌has approved Vera Therapeutics' drug to treat patients with

TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and

Investors are closely watching Vera Therapeutics Inc. (NASDAQ:VERA) as the company awaits the U.S. F

Vera Therapeutics awaits the FDA's July 7 decision on atacicept for IgA nephropathy as investors

As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different grou

As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different grou

Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commerciali

Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets i